LBT Innovations Limited

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 20:04:40 2024-05-22 EDT			5-day change	1st Jan Change
0.018 ^AUD	0.00%		+12.50%	+63.64%

05-08	Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
04-29	LBT Innovations Sells APAS Independence Instrument to NovaCina	MT

LBT Innovations Limtied Announces the Appointment of Damian Lismore as Director

March 24, 2019 at 08:17 pm

LBT INNOVATIONS LIMTIED announced the appointment of Damian Lismore as director effective from 25 March 2019.

Latest news about LBT Innovations Limited

Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024	05-07
LBT Innovations Sells APAS Independence Instrument to NovaCina	04-28	MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data	03-13	MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79%	03-12	MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024	02-28
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher	02-23	MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31%	02-21	MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director	12-13	CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023	11-26	CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring	11-06	MT
LBT Innovations Fully Repays Share Placement Facility	23-10-12	MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27%	23-10-12	MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11%	23-09-04	MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
LBT Innovations Flags AU$13 Million Impairment Charge	23-08-04	MT
LBT Innovations Limited Appoints Rebecca Wilson as Director	23-07-04	CI
LBT Innovations Appoints Chair; Shares Jump 7%	23-07-02	MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director	23-03-29	CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Transcript : LBT Innovations Limited, Q2 2023 Earnings Call, Jan 25, 2023	23-01-24
LBT Innovations, AstraZeneca Partner to Develop APAS Pharma Product	23-01-09	MT
Astrazeneca Partners LBT for Apas Pharma Development	23-01-08	CI
LBT Innovations Limited Receives an Initial Purchase Order from Thermo Fisher Scientific, Inc	22-12-19	CI
LBT Innovations Subsidiary Appoints Thermo Fisher as Exclusive Distributor for Europe	22-12-18	MT

LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LBT INNOVATIONS LIMITED	+63.64%	15.99M
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B